MicroRNA-661 promotes non-small cell lung cancer progression by directly targeting RUNX3

Wang,Yu; Li,Yuqiang; Wu,Bin; Shi,Ce; Li,Chen

doi:10.3892/mmr.2017.6827

MicroRNA-661 promotes non-small cell lung cancer progression by directly targeting RUNX3

Authors:
- Yu Wang
- Yuqiang Li
- Bin Wu
- Ce Shi
- Chen Li
View Affiliations

Affiliations: Department of Molecular Detection, Center for Clinical Biological Samples, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, Liaoning, P.R. China
Published online on: June 21, 2017 https://doi.org/10.3892/mmr.2017.6827
Pages: 2113-2120

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the primary cause of cancer‑associated mortality in men and women worldwide. Increasing evidence indicates that abnormal microRNA (miRNA) expression contributes to the carcinogenesis and progression of multiple human cancers, including non‑small cell lung cancer (NSCLC). Therefore, miRNAs exhibit the potential to act as biomarkers for the diagnosis, treatment and prognosis of human malignancies. miRNA‑661 (miR‑661) has previously been demonstrated to be important in the development of various human cancer types. However, the expression levels, functions and underlying mechanisms of miR‑661 in NSCLC remain to be elucidated. The present study demonstrated that miR‑661 was upregulated in NSCLC tissues and cell lines. In addition, miR‑661 expression levels were significantly correlated with differentiation and tumor stage lymph node metastasis of NSCLC patients. Functional experiments demonstrated that miR-661 downregulation inhibited NSCLC cell proliferation and invasion in vitro. Furthermore, runt‑related transcription factor 3 (RUNX3) was identified as a direct target of miR‑661 in NSCLC. RUNX3 was expressed at a low level in NSCLC tissues and was negatively correlated with the miR‑661 expression level. Further experiments revealed that RUNX3 knockdown significantly rescued the effects of miR‑661 underexpression on NSCLC cell proliferation and invasion. In conclusion, the present findings indicated a role for miR‑661 as an oncogene in NSCLC via direct targeting of RUNX3, thus suggesting that miR‑661 may be used to develop novel therapies for NSCLC patients.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Cushing L, Jiang Z, Kuang P and Lü J: The roles of microRNAs and protein components of the microRNA pathway in lung development and diseases. Am J Respir Cell Mol Biol. 52:397–408. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ebrahimi A and Sadroddiny E: MicroRNAs in lung diseases: Recent findings and their pathophysiological implications. Pulm Pharmacol Ther. 34:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
5	DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
6	Islam KM Monirul, Shostrom V, Kessinger A and Ganti AK: Outcomes following surgical treatment compared to radiation for stage I NSCLC: A SEER database analysis. Lung Cancer. 82:90–94. 2013. View Article : Google Scholar : PubMed/NCBI
7	Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y, Zhao H, Wu J, Zhang Y, Zhao L, et al: National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer. 77:371–375. 2012. View Article : Google Scholar : PubMed/NCBI
8	Laskin JJ and Sandler AB: State of the art in therapy for non-small cell lung cancer. Cancer Invest. 23:427–442. 2005. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
11	Huang Q, Xiao B, Ma X, Qu M, Li Y, Nagarkatti P, Nagarkatti M and Zhou J: MicroRNAs associated with the pathogenesis of multiple sclerosis. J Neuroimmunol 295–296. 148–161. 2016. View Article : Google Scholar
12	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
13	Meltzer PS: Cancer genomics: Small RNAs with big impacts. Nature. 435:745–746. 2005. View Article : Google Scholar : PubMed/NCBI
14	Bao L, Wang L, Wei G, Wang Y, Wuyun G and Bo A: Role of microRNA-4458 in patients with non-small-cell lung cancer. Oncol Lett. 12:3958–3966. 2016.PubMed/NCBI
15	Hu W, Jin P, Ding C and Liu W: miR-19a/b modulates lung cancer cells metastasis through suppression of MXD1 expression. Oncol Lett. 12:1901–1905. 2016.PubMed/NCBI
16	Sahay D, Leblanc R, Grunewald TG, Ambatipudi S, Ribeiro J, Clézardin P and Peyruchaud O: The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget. 6:20604–20620. 2015. View Article : Google Scholar : PubMed/NCBI
17	Maugeri-Saccà M, Coppola V, Bonci D and De Maria R: MicroRNAs and prostate cancer: From preclinical research to translational oncology. Cancer J. 18:253–261. 2012. View Article : Google Scholar : PubMed/NCBI
18	Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et al: miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bartels CL and Tsongalis GJ: MicroRNAs: Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009. View Article : Google Scholar : PubMed/NCBI
20	Li Z, Liu YH, Diao HY, Ma J and Yao YL: MiR-661 inhibits glioma cell proliferation, migration and invasion by targeting hTERT. Biochem Biophys Res Commun. 468:870–876. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhu T, Yuan J, Wang Y, Gong C, Xie Y and Li H: MiR-661 contributed to cell proliferation of human ovarian cancer cells by repressing INPP5J expression. Biomed Pharmacother. 75:123–128. 2015. View Article : Google Scholar : PubMed/NCBI
22	Reddy SD, Pakala SB, Ohshiro K, Rayala SK and Kumar R: MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Res. 69:5639–5642. 2009. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Lee YS, Lee JW, Jang JW, Chi XZ, Kim JH, Li YH, Kim MK, Kim DM, Choi BS, Kim EG, et al: Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell. 24:603–616. 2013. View Article : Google Scholar : PubMed/NCBI
25	Lee KS, Lee YS, Lee JM, Ito K, Cinghu S, Kim JH, Jang JW, Li YH, Goh YM, Chi XZ, et al: Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene. 29:3349–3361. 2010. View Article : Google Scholar : PubMed/NCBI
26	Xiao CZ, Wei W, Guo ZX, Zhang MY, Zhang YF, Wang JH, Shi M, Wang HY and Guo RP: MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. J Cancer Res Clin Oncol. 143:263–273. 2017. View Article : Google Scholar : PubMed/NCBI
27	Jiang H, Ju H, Zhang L, Lu H and Jie K: microRNA-577 suppresses tumor growth and enhances chemosensitivity in colorectal cancer. J Biochem Mol Toxicol. Feb 2–2017.(Epub ahead of print). View Article : Google Scholar
28	Wang H, Li Q, Niu X, Wang G, Zheng S, Fu G and Wang Z: miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. Oncol Lett. 13:435–440. 2017.PubMed/NCBI
29	Gandellini P, Giovannetti E and Nicassio F: MicroRNAs in cancer management: Big challenges for small molecules. Biomed Res Int. 2015:9821562015. View Article : Google Scholar : PubMed/NCBI
30	Mlcochova J, Faltejskova-Vychytilova P, Ferracin M, Zagatti B, Radova L, Svoboda M, Nemecek R, John S, Kiss I, Vyzula R, et al: MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget. 6:38695–38704. 2015.PubMed/NCBI
31	Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY and Wang XW: Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology. 60:872–883. 2014. View Article : Google Scholar : PubMed/NCBI
32	Mei PJ, Bai J, Liu H, Li C, Wu YP, Yu ZQ and Zheng JN: RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol. 137:1823–1830. 2011. View Article : Google Scholar : PubMed/NCBI
33	Dodurga Y, Avci CB, Satiroglu-Tufan NL, Tataroglu C, Kesen Z, Doğan ZO, Yilmaz S and Gündüz C: Detection of deleted in malignant brain tumors 1 and runt-related transcription factor 3 gene expressions in bladder carcinoma. Mol Biol Rep. 39:4691–4695. 2012. View Article : Google Scholar : PubMed/NCBI
34	Sugiura H, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Mori Y, Ogawa R, Katada T, Harata K and Fujii Y: Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 19:713–719. 2008.PubMed/NCBI
35	Jiang Y, Tong D, Lou G, Zhang Y and Geng J: Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology. 75:244–251. 2008. View Article : Google Scholar : PubMed/NCBI
36	Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC, Lu PJ and Hsiao M: Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol. 16:1686–1694. 2009. View Article : Google Scholar : PubMed/NCBI
37	Jili S, Eryong L, Lijuan L and Chao Z: RUNX3 inhibits laryngeal squamous cell carcinoma malignancy under the regulation of miR-148a-3p/DNMT1 axis. Cell Biochem Funct. 34:597–605. 2016. View Article : Google Scholar : PubMed/NCBI
38	Chen F, Liu X, Cheng Q, Zhu S, Bai J and Zheng J: RUNX3 regulates renal cell carcinoma metastasis via targeting miR-6780a-5p/E-cadherin/EMT signaling axis. Oncotarget. Nov 8–2016.(Epub ahead of print).
39	Kim BR, Kang MH, Kim JL, Na YJ, Park SH, Lee SI, Kang S, Joung SY, Lee SY, Lee DH, et al: RUNX3 inhibits the metastasis and angiogenesis of colorectal cancer. Oncol Rep. 36:2601–2608. 2016.PubMed/NCBI
40	Yu GP, Ji Y, Chen GQ, Huang B, Shen K, Wu S and Shen ZY: Application of RUNX3 gene promoter methylation in the diagnosis of non-small cell lung cancer. Oncol Lett. 3:159–162. 2012.PubMed/NCBI
41	Torshabi M, Faramarzi MA, Yazdi M Tabatabaei, Ostad SN and Gharemani MH: Runx3 expression inhibits proliferation and distinctly alters mRNA expression of Bax in AGS and A549 cancer cells. Iran J Pharm Res. 10:355–361. 2011.PubMed/NCBI
42	Lee JM, Shin JO, Cho KW, Hosoya A, Cho SW, Lee YS, Ryoo HM, Bae SC and Jung HS: Runx3 is a crucial regulator of alveolar differentiation and lung tumorigenesis in mice. Differentiation. 81:261–268. 2011. View Article : Google Scholar : PubMed/NCBI